Inhibitors in haemophilia A: The role of VWF/FVIII concentrates - A meeting report

Haemophilia

Volumn 15, Issue 2, 2009, Pages 587-591

  Kaveri, Srinivas ^a,e   Gringeri, A ^b   Heisel Kurth, M ^c   Kreuz, W ^d  

^a INSERM   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c Children's Hospitals   (United States)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CHAPERONE; MANNOSE RECEPTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ALLOIMMUNITY; ANTIBODY COMBINING SITE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; BLEEDING DISORDER; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; CONFERENCE PAPER; DENDRITIC CELL; DRUG MEGADOSE; ENDOCYTOSIS; HELPER CELL; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

BLOOD COAGULATION FACTOR INHIBITORS; CD4 LYMPHOCYTE COUNT; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; MALE; VON WILLEBRAND FACTOR;

EID: 63349098384     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01944.x     Document Type: Conference Paper

References (38)

1. von Willebrand E. Hereditär pseudohemofili. Finska Läkaresällskapets Handlingar 1926; 67: 87-112.
2. Nilsson IM, Blomback M, Jorpes E, Blomback B, Johansson SA. Von Willebrand's disease and its correction with human plasma fraction 1-0. Acta Med Scand 1957; 159: 179-88.
3. Federici AB. The factor VIII/von Willebrand factor complex: Basic and clinical issues. Haematologica 2003; 88: EREP02.
4. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost 1998; 79: 456-65.
5. Kaveri SV, Dasgupta S, Andre S et al. Factor VIII inhibitors: Role of von Willebrand factor on the uptake of factor VIII by dendritic cells. Haemophilia 2007; 13(Suppl. 5): 61-4.
6. Dasgupta S, Navarrete AM, Bayry J et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci USA 2007; 104: 8965-70.
7. Dasgupta S, Repesse Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.
8. Guerois C, Laurian Y, Rothschild C et al. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73: 215-8.
9. Yee TT, Williams MD, Hill FG, Lee CA, Pasi KJ. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb Haemost 1997; 78: 1027-9.
10. Addiego J, Kasper C, Abildgaard C et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-4.
11. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
12. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
13. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
14. Kreuz W, Ettingshausen CE, Auerswald G et al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
15. Hodge G, Saxon B, Revesz T. Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: Relevance to inhibitor formation and tolerance induction. Haemophilia 2006; 12: 133-9.
16. Lin Y, Yang X, Chevrier MC et al. Relationships between factor VIII:AG and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004; 10: 459-69.
17. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: Comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
18. Hodge G, Han P. Effect of intermediate-purity factor VIII (FVIII) concentrate on lymphocyte proliferation and apoptosis: Transforming growth factor-beta is a significant immunomodulatory component of FVIII. Br J Haematol 2001; 115: 376-81.
19. Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
20. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgard U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: The CANAL cohort study. Blood 2007; 109: 4693-7.
21. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
22. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variataion in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996; 2: 95-9.
23. Gensana M, Altisent C, Aznar JA et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369-74.
24. Astermark J, Voorberg J, Lenk H et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003; 9: 567-72.
25. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375-80.
26. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
27. Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 2007; 82: 460-2.
28. Inoue T, Shima M, Takeyama M et al. Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor. Haemophilia 2006; 12: 110-3.
29. Kreuz W, Joseph-Steiner J, Mentzer D et al. Successful immune tolerance therapy of factor VIII inhibitors in children after changing from high to intermediate purity factor VIII concentrate. Ann Hematol 1996; 72(Suppl. 1): 339.
30. Kreuz W, Escuriola-Ettingshausen C, Auerswald G. Immune tolerance induction in haemophilia A patients with inhibitors: The choice of concentrate affecting success. Haematologica 2001; 86(Supp. l4): 16-20.
31. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
32. Gringeri A, Musso R, Mazzucconi MG et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
33. Orsini F, Rothschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
34. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
35. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: Consensus recommendations. Hemophilia 2007; 13(Suppl. 1): 1-22.
36. Kurth MAH, DiMichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-5.
37. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
38. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16(Suppl. 1): S27-31.